Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18;30(71):e202403408.
doi: 10.1002/chem.202403408. Epub 2024 Nov 12.

Total Synthesis of Tosyl-Samroiyotmycin A and Its Biological Profiling

Affiliations

Total Synthesis of Tosyl-Samroiyotmycin A and Its Biological Profiling

Benedikt Kolb et al. Chemistry. .

Abstract

A total synthesis of the enantiopure syn,syn-tosyl-samroiyotmycin A, a C2-symmetric 20-membered antimalarial macrodiolide with syn,syn-configuration of the 8,24-dihydroxy-9,25-dimethyl units and it's enantiopure anti,anti-derivative is described. The synthesis was accomplished utilizing a linear approach in 7 steps and 3 % overall yield via a sequence of diastereoselective methylation of SuperQuat oxazolidinone auxiliary, cross metathesis and Yamaguchi macrolactonization of fully functionalized seco-acids. By a similar approach we gained access to several samroiyotmycin analogues and precursors. Antimalarial activity was tested on multi-resistant (K1) and sensitive (Nf54) P. falciparum strains providing insight into structure activity relationships. Both tosyl-oxazol unit as well as the syn-configuration of the two contiguous stereogenic centers turned out to be beneficial for antiplasmodial activity. For instance, syn,syn-tosyl-samroiyotmycin A showed 3.4 times higher activities than the "tosyl-free" natural product.

Keywords: Antimalarial activity; Biological profiling; Macrocycles; Macrodiolide; Natural products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Some prominent macrodiolides 14.
Scheme 1
Scheme 1
Pathways to samroiyotmycin A syn,syn4 a and its tosylated analogue syn,syn–Ts–4 a.
Scheme 2
Scheme 2
Synthetic routes to seco‐acids syn8 and anti8.
Scheme 3
Scheme 3
Synthesis of samroiyotmycin derivatives and heteroaryl analogues (for further details see Scheme S4, S5).

References

    1. Singh Y. J., Yarrapothu G. R., Vemula R., RSC Adv. 2013, 3, 55–58.
    1. Zhang S., Menche D., Zahler S., Vollmar A. M., Liebl J., Förster F., Pharm. - Int. J. Pharm. Sci. 2015, 70, 610–615. - PubMed
    1. Gronewold T. M. A., Sasse F., Lünsdorf H., Reichenbach H., Cell Tissue Res. 1999, 295, 121–129. - PubMed
    1. Huang W., Wu Q., Zhang M., Kong Y., Cao P., Zheng W., Xu J., Ye M., Cancer Lett. 2015, 356, 862–871. - PubMed
    1. Huang W., Ye M., Zhang L., Wu Q., Zhang M., Xu J., Zheng W., Mol. Cancer 2014, 13, 150. - PMC - PubMed

MeSH terms

LinkOut - more resources